Insider Transactions in Q1 2022 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2022
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,137
+1.21%
|
$6,411
$3.55 P/Share
|
|
Jan 04
2022
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
278
+0.32%
|
$8,618
$31.58 P/Share
|
|
Jan 04
2022
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
318
+37.06%
|
$9,858
$31.58 P/Share
|
|
Jan 04
2022
|
Marc A Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
657
+37.01%
|
$20,367
$31.58 P/Share
|
|
Jan 04
2022
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
199
+28.72%
|
$6,169
$31.58 P/Share
|
|
Jan 04
2022
|
Malcolm Salter Director |
BUY
Grant, award, or other acquisition
|
Direct |
428
+3.62%
|
$13,268
$31.58 P/Share
|
|
Jan 04
2022
|
Adam Crystal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-26.53%
|
$480,000
$32.13 P/Share
|
|
Jan 04
2022
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.33%
|
$90,000
$6.49 P/Share
|